Spiruchostatin A inhibits proliferation and differentiation of fibroblasts from patients with pulmonary fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 46, Issue 5, 2012, Pages 687-694

  Davies, Elizabeth R ^a,c   Haitchi, Hans Michael ^a,c   Thatcher, Thomas H ^d   Sime, Patricia J ^d   Kottmann, R Matthew ^d   Ganesan, Arasu ^b   Packham, Graham ^c   O'Reilly, Katherine M A ^c   Davies, Donna E ^a,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Histone deacetylase inhibitor; Myofibroblast; Proliferation; Pulmonary fibrosis; Spiruchostatin A

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; METHYLENE BLUE; SPIRUCHOSTATIN A; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AGED; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CASE REPORT; CELL CULTURE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FIBROBLAST; FIBROSING ALVEOLITIS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LUNG BIOPSY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HISTONE DEACETYLASE INHIBITORS; HUMANS; PEPTIDES, CYCLIC; POLYMERASE CHAIN REACTION; PULMONARY FIBROSIS;

EID: 84860529331     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2011-0040OC     Document Type: Article

References (39)

1. Valeyre D, Freynet O, Dion G, Bouvry D, Annesi-Maesano I, Nunes H. Epidemiology of interstitial lung diseases. Presse Med 2010;39:53-59.
2. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008;3:8.
3. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multi-disciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
4. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174:810-816. (Pubitemid 44511663)
5. King TE Jr., Schwarz MI, Brown K, Tooze JA, Colby TV, Waldron JA Jr., Flint A, Thurlbeck W, Cherniack RM. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-1032. (Pubitemid 32971653)
6. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis. 2010;4:367-388.
7. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151. (Pubitemid 32096342)
8. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001;99:308-219.
9. Nicholson AG, Fulford LG, Colby TV, du Bois RM, Hansell DM, Wells AU. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:173-177. (Pubitemid 34765453)
10. Golec M, Lambers C, Hofbauer E, Geleff S, Bankier A, Czerny M, Ziesche R. Assessment of gene transcription demonstrates connection with the clinical course of idiopathic interstitial pneumonia. Respiration 2008;76:261-269.
11. Ramos C, Montano M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M, Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 2001;24:591-598. (Pubitemid 32442767)
12. Zheng YG, Wu J, Chen Z, Goodman M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev 2008;28:645-687.
13. de Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-749. (Pubitemid 36399066)
14. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications. Int J Oncol 2008;33:637-646.
15. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002;1:287-299. (Pubitemid 37361445)
16. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 2009;107:600-608.
17. Wang Z, Chen C, Finger SN, Kwajah S, Jung M, Schwarz H, Swanson N, Lareu FF, Raghunath M. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J 2009; 34:145-155.
18. Crabb SJ, Howell M, Rogers H, Ishfaq M, Yurek-George A, Carey K, Pickering BM, East P, Mitter R, Maeda S, et al. Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A. Biochem Pharmacol 2008;76:463-475.
19. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian XZ, Mills E, Berghs SC, Carey N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-589. (Pubitemid 351184977)
20. Davies ER, Haitchi HM, Ganesan A, Packham G, O'Reilly KMA, Davies DE, editors. Spiruchostatin A inhibits proliferation and differentiation of primary fibroblasts from patients with interstitial lung disease [abstract]. Am J Respir Crit Care Med 2010;181:A2994.
21. Yurek-George A, Habens F, Brimmell M, Packham G, Ganesan A. Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor. J Am Chem Soc 2004;126:1030-1031. (Pubitemid 38140727)
22. Oliver MH, Harrison NK, Bishop JE, Cole PJ, Laurent GJ. A rapid and convenient assay for counting cells cultured in microwell plates: application for assessment of growth factors. J Cell Sci 1989;92:513-518. (Pubitemid 19083806)
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408. (Pubitemid 34164012)
24. Tare RS, Howard D, Pound JC, Roach HI, Oreffo RO. Tissue engineering strategies for cartilage generation: micromass and three dimensional cultures using human chondrocytes and a continuous cell line. Biochem Biophys Res Commun 2005;333:609-621. (Pubitemid 40848333)
25. Masuoka YAN, Shin-ya K, Furihata K, Nagai K, Suzuki K, Hayakawa Y, Seto H. Spiruchostatins A and B, novel gene expression-enhancing substances produced by Pseudomonas sp. Tetrahedron Letter 2001;42: 41-44. (Pubitemid 32011701)
26. Li CY, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995;270:4971-4974.
27. Yoo YD, Choi JY, Lee SJ, Kim JS, Min BR, Lee YI, Kang YK. TGF-beta-induced cell-cycle arrest through the p21(WAF1/CIP1)-G1 cyclin/Cdks-p130 pathway in gastric-carcinoma cells. Int J Cancer 1999;83:512-517. (Pubitemid 29489867)
28. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, Brosch G, Wintersberger E, Seiser C. Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 1999;19: 5504-5511. (Pubitemid 29339908)
29. Waby JS, Chirakkal H, Yu C, Griffiths GJ, Benson RS, Bingle CD, Corfe BM. Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line. Mol Cancer 2010;9:275.
30. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters- Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995; 95:1861-1868.
31. Coward WR, Watts K, Feghali-Bostwick CA, Knox A, Pang L. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol Cell Biol 2009; 29:4325-4339.
32. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition. Am J Physiol Lung Cell Mol Physiol 2009;297: L864-L870.
33. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol 2004;24:8374-8385. (Pubitemid 39245060)
34. McKinsey TA, Olson EN. Cardiac histone acetylation: therapeutic opportunities abound. Trends Genet 2004;20:206-213. (Pubitemid 38369192)
35. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, Verdin E. Enzymatic activity associated with Class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57. (Pubitemid 34127770)
36. Abbas A, Gupta S. The role of histone deacetylases in prostate cancer. Epigenetics 2008;3:300-309.
37. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004;59:177-189. (Pubitemid 38481229)
38. Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, Lee SH, Park WS, Yoo NJ, Lee JY, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. Acta Path Microbiol Immunol Scand 2005;113:264-118.
39. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 2008;25:183-189.